LifeSciences BC > News > Member Announcements > 2015 > Qu Biologics Opens Clinical Trial Sites in Edmonton and Toronto for Crohn’s Disease Clinical Trial

Print Friendly, PDF & Email

Member Announcements

Qu Biologics Opens Clinical Trial Sites in Edmonton and Toronto for Crohn’s Disease Clinical Trial

April 24, 2015 – Qu Biologics Inc.

Vancouver, British Columbia – April 24, 2015 –   Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body’s normal immune function in the targeted diseased organ, announced today it has opened two new clinical trial sites in Edmonton, Alberta and Toronto, Ontario to enroll participants in its Crohn’s disease clinical trial.

Qu Biologics’ Crohn’s disease clinical trial is a randomized, placebo-controlled research trial enrolling participants living with moderate-to-severe Crohn’s disease. The trial involves the use of Qu Biologics’ QBECO SSI, a novel immunotherapy treatment derived from components of inactivated E. coli bacteria, designed to stimulate an innate immune response in the gastrointestinal tract to reverse the underlying chronic inflammation related to Crohn’s disease. The clinical trial takes place in Vancouver, Edmonton and Toronto.

Qu Biologics’ CEO Dr. Hal Gunn commented, “Opening trial sites in Edmonton and Toronto allow participants from other provinces to access our clinical trial closer to home.”   He added, “These two new clinical trial sites will also help us accelerate our goal of completing trial enrollment by Q3 2015 and obtaining primary results by the end of the year.”

For more information about the clinical trial, please visit www.qucrohnstrial.com or call 1.855.209.9680.

About Qu Biologics
Qu Biologics develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies that aim to restore the body’s normal immune response. SSIs are designed to stimulate an innate immune response in targeted organs or tissues to reverse the chronic inflammation underlying many illnesses, including cancer and other immune-related diseases. The company is currently recruiting participants for a clinical trial in Crohn’s disease and a Phase 2a open-label clinical trial in recurrent non-small cell lung cancer to study SSI treatment. A clinical trial in ulcerative colitis has received Health Canada approval and will begin in Q2 2015.

Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body’s immune response to chronic disease, Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally, and Chief Scientific Officer Dr. David Mullins, Assistant Professor of Microbiology and Immunology in the Norris Cotton Cancer Center at the Geisel School of Medicine at Dartmouth, and recognized expert in immune cell trafficking to tumours.   For more information, visit www.qubiologics.com and www.qucrohnstrial.com.

Julie Jang
Director, Communications
Qu Biologics Inc.
604.734.1450 ext.41491
julie@qubiologics.com

Qu Biologics Inc. cautions you that statements included in this release that are not a description of historical facts may contain forward-looking statements. These forward-looking statements are only predictions and may involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements. Qu Biologics does not assume any obligation to update any forward-looking statements except as required by law.